We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lupin Expands U.S. Generics Presence Via $880M Gavis Deal
Lupin Expands U.S. Generics Presence Via $880M Gavis Deal
Indian generics maker Lupin is set to buy privately held U.S. generics maker Gavis Pharmaceuticals for $880 million, a move that expands Lupin’s share of the U.S. generics market.